Clinical Trial

Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies

Name: Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies — clinical trial record (NCT07446270)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Trial Details

NCT Number	NCT07446270
Lead Sponsor	Chinese PLA General Hospital
Conditions	Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer
Enrollment	90 participants
Start Date	2026-03-03
Primary Completion	2027-10-30 (estimated)
Study Completion	2028-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-03